2016

Home » FAQs » 2016

2016

♦  First commercial exhibit of Imagio® OA/US technology at European Society of Breast Imaging in Paris.
♦  Announces interim results from the company’s multicenter, European MAESTRO post-market surveillance and clinical follow-up study. The data were presented at a clinical symposium at the Annual Scientific Meeting of the European Society of Breast Imaging (EUSOBI) in Paris, the second largest conference in the world dedicated to breast cancer imaging. “We look forward to the delivery of the first Imagio® OA/US systems in the Netherlands, UK and Germany early next year,” Seno CEO Tom Umbel said.
♦  Tom Umbel named Chief Executive Officer. Mr. Umbel takes the helm from Tom Miller, Seno Medical’s President, who was serving as interim CEO following the departure of founder Janet Campbell.
♦ Completes active enrollment of subjects in its international MAESTRO post-market surveillance clinical study.

2018-10-19T15:20:15+00:00